TP53 R280T

CI-VAR-00003810Explore in graph →NP_000537.3:p.Arg280ThrNM_000546.5:c.839G>CClinVar 12368 CIViC 1698 rs121912660

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
TP53 R280T	MDM2 Inhibitor AMGMDS3	Predictive	D	Supports Resistance	4	accepted	EID4890 Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
12368	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts	2	Nasopharyngeal carcinoma; Li-Fraumeni syndrome; Acute myeloid leukemia; Hereditary cancer-predisposing syndrome; Malignant tumor of urinary bladder; Li-Fraumeni syndrome 1	germline/somatic	6	Aug 27, 2024	clinvar